Hospital Clinic of Barcelona, Otolaryngology Department, Barcelona, Spain; Universitat de Barcelona, Facultat de Medicina i Ciències de la Salut, Departament de Cirurgia i Especialitats Mèdicoquirúrgiques, Barcelona, Spain; Institut d'Investigacions Biomèdiques Agusti Pi Sunyer (IDIBAPS), Barcelona, Spain.
Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain.
Braz J Otorhinolaryngol. 2024 Nov-Dec;90(6):101493. doi: 10.1016/j.bjorl.2024.101493. Epub 2024 Aug 10.
To determine whether routinary walking activity and the derived neutrophil-to-lymphocyte ratio are associated with outcomes in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
This multicenter retrospective cohort study included 64 patients diagnosed with recurrent and/or metastatic squamous cell carcinoma of head and neck and treated with immunotherapy (Programmed Death-1 and Programmed Death-ligand-1 proteins inhibitors) at two tertiary centers. We compared a group that performed uninterrupted physical activity for 1 h per day and controls who performed no activity. The derived neutrophil-to-lymphocyte ratio was calculated as follows: [neutrophils / (leukocytes - neutrophils)]. Progression-free survival and overall survival were evaluated.
We included 28 (44%) and 36 (56%) patients in the activity and non-activity groups, respectively. Patient characteristics, treatment details, and tumor Programmed Death-ligand-1 expression were not associated with either progression-free survival or overall survival. Physical activity was an independent beneficial factor for progression-free survival (p < 0.001) and overall survival (p < 0.001). By contrast, a derived neutrophil-to-lymphocyte ratio <3.5 was an independent beneficial factor for overall survival (p = 0.013), but not for progression-free survival (p = 0.328).
Walking one hour per day and having a high proportion of lymphocytes to neutrophiles (expressed as a low derived neutrophil-to-lymphocyte ratio) independently predict a better prognosis in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck treated with immunotherapy.
III.
确定常规步行活动和由此产生的中性粒细胞与淋巴细胞比值是否与复发性和/或转移性头颈部鳞状细胞癌患者的结局相关。
这是一项多中心回顾性队列研究,纳入了在两个三级中心接受免疫治疗(程序性死亡受体-1 和程序性死亡受体配体-1 蛋白抑制剂)的 64 例复发性和/或转移性头颈部鳞状细胞癌患者。我们比较了一组每天不间断进行 1 小时体育活动的患者和对照组(无活动组)。由此产生的中性粒细胞与淋巴细胞比值的计算方法如下:[中性粒细胞/(白细胞-中性粒细胞)]。评估无进展生存期和总生存期。
我们将 28 例(44%)和 36 例(56%)患者分别纳入活动组和非活动组。患者特征、治疗细节和肿瘤程序性死亡配体-1 表达与无进展生存期或总生存期均无相关性。体力活动是无进展生存期(p<0.001)和总生存期(p<0.001)的独立有益因素。相比之下,中性粒细胞与淋巴细胞比值<3.5 是总生存期的独立有益因素(p=0.013),但对无进展生存期无影响(p=0.328)。
每天步行 1 小时,淋巴细胞与中性粒细胞的比例较高(表现为较低的中性粒细胞与淋巴细胞比值),与接受免疫治疗的复发性和/或转移性头颈部鳞状细胞癌患者的预后较好相关。
III 级。